RESUMO
BACKGROUND: Crohn's disease may be refractory to conventional treatments including corticosteroids and immunosuppressives. Recent studies suggest TNF-alpha blocking agents may be effective in maintaining remission in Crohn's disease. OBJECTIVES: To conduct a systematic review of the evidence for the effectiveness of TNF-alpha blocking agents in the maintenance of remission in patients with Crohn's disease. SEARCH STRATEGY: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and the IBD/FBD Review Group Specialized Trials Register were searched for relevant studies published between 1966-2007. Manual searches of references from potentially relevant papers were performed to identify additional studies. Experts in the field and study authors were contacted to identify unpublished data. SELECTION CRITERIA: Randomized controlled trials involving patients > 18 years with Crohn's disease who had a clinical response or clinical remission with a TNF-alpha blocking agent, or patients with Crohn's disease in remission but unable to wean corticosteroids, who were then randomized to maintenance of remission with a TNF-alpha blocking agent or placebo DATA COLLECTION AND ANALYSIS: Two independent authors performed data extraction and assessment of the methodological quality of each trial. Outcome measures reported in the primary studies included clinical remission, clinical response, and steroid-sparing effects. MAIN RESULTS: Nine studies met all inclusion criteria. Four different anti-TNF-alpha agents were evaluated (infliximab in 3 studies, CDP571 in 3 studies, adalimumab in 2 studies, and certolizumab in 1 study). There is evidence from three randomized controlled trials that infliximab maintains clinical remission (RR 2.50; 95% CI 1.64 to 3.80), maintains clinical response (RR 1.66; 95% CI 1.00 to 2.76), has corticosteroid-sparing effects (RR 3.13; 95% CI 1.25 to 7.81), and maintains fistula healing (RR 1.87; 95% CI 1.15 to 3.04) in patients with Crohn's disease with a response to infliximab induction therapy. There were no significant differences in remission rates between infliximab doses of 5 mg/kg or 10 mg/kg. There is evidence from two randomized controlled trials that adalimumab maintains clinical remission (RR 2.86; 95% CI 2.01 to 4.02), maintains clinical response (RR 2.69; 95% CI 1.88 to 3.86), and has corticosteroid-sparing effects (RR 2.81, 95% CI 1.46 to 5.43) in patients with Crohn's disease who have responded or entered remission with adalimumab induction therapy. There were no significant differences in remission rates between adalimumab 40 mg weekly or every other week. There is evidence from one randomized controlled trial that certolizumab pegol maintains clinical remission (RR 1.68; 95% CI 1.30 to 2.16) and maintains clinical response (RR 1.74; 95% CI 1.41 to 2.13) in patients who have responded to certolizumab induction therapy. There is no evidence to support the use of CDP571 for the maintenance of remission in Crohn's disease. AUTHORS' CONCLUSIONS: Infliximab 5 mg/kg or 10 mg/kg, given every 8 weeks, is effective for the maintenance of remission and maintenance of fistula healing in patients who have responded to infliximab induction therapy. Adalimumab 40 mg weekly or every other week is effective for the maintenance of remission in patients who have responded to adalimumab induction therapy. Certolizumab pegol 400 mg every 4 weeks is effective for the maintenance of remission in patients who have responded to certolizumab induction therapy. No comparative trials have evaluated the relative efficacy of these agents. Adverse events are similar in the infliximab, adalimumab, and certolizumab groups compared with placebo, but study size and duration generally are insufficient to allow an adequate assessment of serious adverse events associated with long-term use.
Assuntos
Anti-Inflamatórios/uso terapêutico , Doença de Crohn/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adalimumab , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Humanizados , Certolizumab Pegol , Humanos , Fragmentos Fab das Imunoglobulinas/uso terapêutico , Infliximab , Polietilenoglicóis/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto , Indução de RemissãoRESUMO
BACKGROUND: The outcome of orthotopic liver transplantation (OLTX) in patients retransplanted for severe hepatitis B virus (HBV) in the first allograft has been poor due to high rates of HBV reinfection and even more aggressive disease in the second graft. Recent data suggest that hepatitis B immunoglobulin (HBIg) given after transplantation can be successful in delaying or preventing HBV reinfection in patients transplanted for chronic hepatitis B cirrhosis. We report the successful retransplantation of patients who developed recurrent or de novo hepatitis B after OLTXY. METHODS: Using similar HBIg regimens, two centers retransplanted seven patients after they developed recurrent or de novo hepatitis B in the first allograft. At retransplantation all seven patients were HBs antigen (Ag) positive; four patients were positive for HBeAg and HBV DNA by immunoblot assay, two patients were negative for HBeAg and HBV DNA, and one patient was positive for HBV DNA and negative for HBeAg. All patients were either HDV Ag or anti-HDV negative. One patient was anti-HCV positive. All patients received HBIg infusions after retransplantation to maintain serum anti-HBs levels >500 IU/L indefinitely. RESULTS: After retransplantation, six of seven patients are alive (86%): all are without evidence of HBV recurrence with serum negative for HBsAg, HBeAg, and HBV DNA by immunoblot assay. Liver biopsies are normal on routine studies with immunohistochemical stains for HBcAg and HBsAg also being negative. Mean follow-up of these six patients is 40.1 months (range 21-63 months). One patient (14%) developed HBV reinfection 7 months after his second transplant, in spite of maintaining target anti-HBs levels. He maintained stable liver function with minimal evidence of clinical hepatitis B, but died 8 months later from an unrelated stroke. CONCLUSIONS: We conclude that patients with recurrent or de novo hepatitis B after OLTX can be successfully retransplanted using aggressive immunoprophylaxis to prevent HBV reinfection. The failure of HBIg therapy in one patient underscores the need for other effective adjunctive anti-HBV modalities.
Assuntos
Hepatite B/etiologia , Transplante de Fígado/efeitos adversos , Reoperação , Adulto , Arginina/genética , DNA Viral/análise , Glicina/genética , Rejeição de Enxerto/virologia , Sobrevivência de Enxerto/fisiologia , Anticorpos Anti-Hepatite/administração & dosagem , Anticorpos Anti-Hepatite/uso terapêutico , Hepatite B/imunologia , Hepatite B/prevenção & controle , Antígenos de Superfície da Hepatite B/sangue , Antígenos E da Hepatite B/sangue , Vírus da Hepatite B/genética , Vírus da Hepatite B/isolamento & purificação , Humanos , Imunização Passiva , Immunoblotting , Imunoglobulinas/imunologia , Masculino , Pessoa de Meia-Idade , Mutação Puntual , Transplante Homólogo/imunologia , Transplante Homólogo/patologiaRESUMO
Infliximab (Remicade, Centocor, Inc.) is an intravenously administered monoclonal antibody to TNF proven effective in the treatment of moderate to severe Crohn's disease (CD). Its introduction in October 1998 was heralded by some as the most important addition to therapy for this condition in 50 years. Since then, additional indications have been added as efficacy has been proven in fistulising CD and in rheumatoid arthritis. Even though the costs associated with a single dose are several thousand US dollars, more than 150,000 patients have received infusions since its approval.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Doença de Crohn/tratamento farmacológico , Fármacos Gastrointestinais/uso terapêutico , Anticorpos Monoclonais/efeitos adversos , Anticorpos Monoclonais/imunologia , Ensaios Clínicos Fase III como Assunto , Contraindicações , Aprovação de Drogas , Farmacoeconomia , Previsões , Guias como Assunto , Cefaleia/induzido quimicamente , Humanos , Infliximab , Infusões Intravenosas , Náusea/induzido quimicamente , Projetos Piloto , Doença do Soro/induzido quimicamente , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Fator de Necrose Tumoral alfa/imunologia , Fator de Necrose Tumoral alfa/fisiologiaAssuntos
Transtornos de Deglutição/diagnóstico por imagem , Estenose Esofágica/diagnóstico por imagem , Artéria Subclávia/anormalidades , Adulto , Transtornos de Deglutição/diagnóstico , Transtornos de Deglutição/etiologia , Diagnóstico Diferencial , Estenose Esofágica/diagnóstico , Estenose Esofágica/etiologia , Humanos , Masculino , Radiografia , Artéria Subclávia/diagnóstico por imagemRESUMO
BACKGROUND: The subjectivity of the West-Haven criteria (WHC) hinders hepatic encephalopathy (HE) evaluation. The new HE classification has emphasised assessment of orientation. The modified-orientation log (MO-log, eight questions, scores 0-24; 24 normal) is adapted from a validated brain injury measure. AIM: To validate MO-log for HE assessment in cirrhosis. METHODS: Cirrhotics admitted with/without HE were administered MO-log. We collected cirrhosis/HE details, admission/daily MO-logs and WHC (performed by different examiners), time to reach normal mentation (MO-log ≥23) and MO-log/WHC change (Δ) over day 1. Outcomes were in-hospital mortality, duration to normal mentation and length-of-stay (LOS). Regressions were performed for each outcome. MO-log inter-rater reliability was measured. RESULTS: Ninety-six HE (55 ± 8 years, MELD 21) and 20 non-HE (54 ± 5 years, MELD 19) in-patients were included. In HE patients, median admission WHC was 3 (range 1-4). Mean MO-log was 12 ± 8 (range 0-22). Their LOS was 6 ± 5 days and 13% died. Time to reach normal mentation was 2.4 ± 1.7 days. Concurrent validity: there was a significant negative correlation between admission MO-log and WHC (r = -0.79, P < 0.0001). Discriminant validity: admission MO-logs were significantly lower in those who died (7 vs. 12, P = 0.03) and higher in those admitted without HE (23.6 vs. 12, P < 0.0001). MO-log improved in 69% on day 1 (ΔMO-log 4 ± 8) which was associated with lower duration to normal mentation (2 vs. 3.5 days, P = 0.03) and mortality (3% vs.43%, P < 0.0001), not ΔWHC. Regression models for all outcomes included admission/ΔMO-log but not WHC as a predictor. Inter-rater reliability: ICC for MO-log inter-rater observations was 0.991. CONCLUSIONS: Modified-orientation log is a valid tool for assessing severity and is better than West-Haven criteria in predicting outcomes in hospitalised hepatic encephalopathy patients.
Assuntos
Encefalopatia Hepática/diagnóstico , Encefalopatia Hepática/fisiopatologia , Perfil de Impacto da Doença , Feminino , Encefalopatia Hepática/mortalidade , Mortalidade Hospitalar , Humanos , Tempo de Internação , Cirrose Hepática/diagnóstico , Cirrose Hepática/fisiopatologia , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Reprodutibilidade dos Testes , Índice de Gravidade de Doença , Inquéritos e QuestionáriosAssuntos
Transplante de Fígado , Complicações Pós-Operatórias/epidemiologia , Embolia Pulmonar/epidemiologia , Trombose/epidemiologia , Filtros de Veia Cava , Adulto , Feminino , Seguimentos , Hemorragia Gastrointestinal/etiologia , Humanos , Incidência , Transplante de Fígado/métodos , Masculino , Pessoa de Meia-Idade , Embolia Pulmonar/terapia , Estudos Retrospectivos , Fatores de Risco , Tromboembolia/epidemiologia , Tromboembolia/cirurgia , Trombose/cirurgia , Fatores de Tempo , Veia Cava InferiorAssuntos
Hepatite B/cirurgia , Cirrose Hepática/cirurgia , Transplante de Fígado , Complicações Pós-Operatórias , Adulto , DNA Viral/análise , Seguimentos , Hepatite B/complicações , Hepatite B/prevenção & controle , Vírus da Hepatite B/isolamento & purificação , Humanos , Imunoglobulinas Intravenosas/uso terapêutico , Terapia de Imunossupressão/métodos , Cirrose Hepática/virologia , Transplante de Fígado/patologia , Transplante de Fígado/fisiologia , Masculino , Pessoa de Meia-Idade , Recidiva , ReoperaçãoAssuntos
Colite Ulcerativa/tratamento farmacológico , Doença de Crohn/tratamento farmacológico , Administração Tópica , Antibacterianos/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Aspirina/uso terapêutico , Colite Ulcerativa/fisiopatologia , Colite Ulcerativa/cirurgia , Colite Ulcerativa/terapia , Doença de Crohn/fisiopatologia , Doença de Crohn/cirurgia , Doença de Crohn/terapia , Citocinas/uso terapêutico , Fármacos Gastrointestinais/uso terapêutico , Glucocorticoides , Humanos , Imunossupressores/uso terapêutico , Imunoterapia , Integrinas/antagonistas & inibidores , Leucaférese , Nutrição Parenteral , Proctocolectomia Restauradora , Sulfassalazina/uso terapêutico , Linfócitos T/imunologiaRESUMO
Enteral strictures are a frequent indication for surgery in Crohn's disease. Postoperative complications are increased in patients with poor preoperative nutritional status, which is common in this patient population. We present a 49-year-old female with longstanding Crohn's disease admitted to our Digestive Health Center with four weeks of increasing abdominal symptoms and radiographic evidence of small-bowel obstruction caused by ileal stricture. Given her poor nutritional status, our team elected to pursue metallic enteral stenting as a bridge to surgical resection. Two Wallstents were placed; luminal patency was subsequently confirmed by a fluoroscopic study. The patient tolerated regular diet and was discharged. When seen in follow-up, she remained asymptomatic and wished to defer surgical intervention indefinitely.
Assuntos
Doença de Crohn/cirurgia , Doenças do Íleo/cirurgia , Obstrução Intestinal/cirurgia , Intestino Delgado , Stents , Meios de Contraste , Doença de Crohn/diagnóstico por imagem , Enema , Feminino , Humanos , Doenças do Íleo/diagnóstico por imagem , Obstrução Intestinal/diagnóstico por imagem , Pessoa de Meia-Idade , Tomografia Computadorizada por Raios XRESUMO
Sclerosing cholangitis is usually diagnosed by clinical findings coupled with radiographic imaging of the bile ducts by ERCP. Direct imaging of both the intra- and extrahepatic biliary tree provides an opportunity to further study this disorder and its potential complications such as biliary malignancy. However, endoscopic visualization of the intrahepatic bile ducts in sclerosing cholangitis is potentially limited by the size of available cholangioscopes and the presence of strictures. Below, we report our initial results using a 0.8-mm fiberoptic endoscope placed through a partially steerable 1.8-mm guide catheter. The system allows visualization of the intrahepatic biliary tree beyond areas of stricture in the more distal ducts.
Assuntos
Colangite Esclerosante/diagnóstico , Endoscopia do Sistema Digestório/instrumentação , Endoscopia do Sistema Digestório/métodos , Tecnologia de Fibra Óptica , HumanosRESUMO
Understanding the relationships of intraluminal manometric events to bolus transit through the esophagus has been limited by conventional manometric analysis methods. We reconstructed pressure events in the axial direction in order (1) to describe the peristaltic pressure wave as it propagates through the esophagus in the direction of the bolus and (2) to determine what sampling interval along the esophageal length is required for accurate representation. Esophageal manometric studies using the stepwise withdrawal method were performed in 10 asymptomatic volunteers. Propagating wave forms were created at 0.2-sec intervals and analyzed in static and dynamic fashion from averaged waves at each 1-3 cm of esophageal length. A distinctive and similar appearance to the propagating wave form, comprised of three sequential but overlapping contraction segments in the esophageal body, was present in nine subjects. The propagating wave decelerated as it approached the second region (smooth-muscle esophagus) and extended over as much as 15.1+/-0.7 cm of esophageal length. No significant differences in wave front propagation, length, or velocity could be determined if the sampling interval increased from 1 to 3 cm of esophageal length, but peak amplitudes were reduced by as much as 14.2%. We conclude that the esophageal pressure wave, when viewed in the direction of bolus transit, is broad and typically comprised of three sequential contraction components. Sampling at >1-cm intervals along the esophageal length significantly alters the wave appearance and may be unsatisfactory in the distal esophagus. Axial transformations of manometric data potentially will provide better information concerning the neuromuscular control of peristalsis and events responsible for bolus movement.
Assuntos
Esôfago/fisiologia , Pressão , Adulto , Feminino , Humanos , Masculino , Manometria , Peristaltismo/fisiologia , Valores de Referência , Processamento de Sinais Assistido por ComputadorRESUMO
The relationship between chronic inflammatory conditions and malignancy is complex. We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab. The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab. The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab. The lymphoma presented with pleural effusions, mediastinal and cervical adenopathy, and no gastrointestinal lesion. We describe the implications of these cases for the use of immunomodulatory therapy in CD and the questionable association between CD and lymphoma.
Assuntos
Anticorpos Monoclonais/efeitos adversos , Doença de Crohn/complicações , Fármacos Gastrointestinais/efeitos adversos , Linfoma/induzido quimicamente , Adulto , Anticorpos Monoclonais/uso terapêutico , Doença de Crohn/tratamento farmacológico , Fármacos Gastrointestinais/uso terapêutico , Humanos , Infliximab , Linfoma/complicações , Masculino , Pessoa de Meia-IdadeRESUMO
IL-18, a novel immunoregulatory cytokine with potent IFN-gamma-inducing activities, may play an important role in Th1-mediated chronic inflammatory disorders. The aim of the present study was to characterize the expression and localization of IL-18 in colonic specimens and isolated mucosal cell populations from patients with Crohn's disease (CD), a prototypic Th1-mediated disorder. Using a semiquantitative RT-PCR protocol, IL-18 mRNA transcripts were found to be increased in freshly isolated intestinal epithelial cells (IEC) and lamina propria mononuclear cells (LPMC) from CD compared with ulcerative colitis (UC) and noninflamed control (cont) patients, and were more abundant in IEC compared with LPMC. Immunohistochemical analysis of surgically resected colonic tissues localized IL-18 to both LPMC (specifically, macrophages and dendritic cells) as well as IEC. Staining was more intense in CD compared with UC and cont, and in involved (inv) vs noninvolved (n inv) areas. Western blot analysis revealed that an 18. 3-kDa band, consistent with both recombinant and mature human IL-18 protein, was found predominantly in CD vs UC intestinal mucosal biopsies; a second band of 24 kDa, consistent with the inactive IL-18 precursor, was detected in n inv areas from both CD and UC biopsies and was the sole form found in noninflamed cont. To our knowledge, this report is the first describing increased expression of IL-18 in a human Th1-mediated chronic inflammatory disease. In addition, our studies further support the concept that IEC and dendritic cells may possess important immunoregulatory functions in both normal, as well as pathological, mucosal immunity.